Scholarlink

<p><i>Candida auris</i> is an emerging fungus which exhibits characteristic features that make it a significant global health challenge, including its high capacity for dissemination in hospital environments, as well as its multidrug resistance. Nanotechnology has emerged as an innovative and promising strategy to tackle the limitations of conventional treatment. The aim of this study was to review the current prospects for the use of nanosystems in the treatment of infections caused by this fungus, highlighting recent advances and the associated challenges. A total of 44 articles published between 2014 and 2025 were analyzed based on the nanocarriers used, their physicochemical characteristics and the in vitro and in vivo studies. Among the nanosystems investigated were polymeric nanoparticles (NPs), liposomes, nanoemulsions and nanofibers. These systems proved to be effective in encapsulating antifungals such as amphotericin B, fluconazole and caspofungin, as well as other drugs, providing significant improvements in antifungal efficacy, especially against <i>Candida auris</i> biofilms. Encapsulation in NPs enhanced the action of the drugs, reduced toxicity, increased bioavailability and promoted a controlled drug release. In vivo trials, although limited in number, suggest that these systems have clinical potential, with low toxicity and promising results. Despite these remarkable merits, further studies are needed to assess the safety and efficacy in humans. In addition, some in vivo experiments present inadequate methodologies, being carried out with low sample numbers and without details on randomization. Moreover, clinical studies should be encouraged to obtain more detailed results, including long-term toxicity, pharmacokinetic and pharmacodynamic parameters of these nanosystems.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Can Pharmaceutical Nanotechnology Improve Candida auris treatment?

  • 期刊论文

  • 发表日期：

    2025年7月31日

查看全文
  • Rebeca Medeiros de Oliveira,
  • Tatielle do Nascimento,
  • Gabriela Lopes Gama e Silva,
  • Mariana Sato de Souza-Bustamante Monteiro,
  • Ralph Santos-Oliveira,
  • Franklin Chimaobi Kenechukwu,
  • Stelia Carolina Mendez Sanchez,
  • Eduardo Ricci-Junior

摘要

Candida auris is an emerging fungus which exhibits characteristic features that make it a significant global health challenge, including its high capacity for dissemination in hospital environments, as well as its multidrug resistance. Nanotechnology has emerged as an innovative and promising strategy to tackle the limitations of conventional treatment. The aim of this study was to review the current prospects for the use of nanosystems in the treatment of infections caused by this fungus, highlighting recent advances and the associated challenges. A total of 44 articles published between 2014 and 2025 were analyzed based on the nanocarriers used, their physicochemical characteristics and the in vitro and in vivo studies. Among the nanosystems investigated were polymeric nanoparticles (NPs), liposomes, nanoemulsions and nanofibers. These systems proved to be effective in encapsulating antifungals such as amphotericin B, fluconazole and caspofungin, as well as other drugs, providing significant improvements in antifungal efficacy, especially against Candida auris biofilms. Encapsulation in NPs enhanced the action of the drugs, reduced toxicity, increased bioavailability and promoted a controlled drug release. In vivo trials, although limited in number, suggest that these systems have clinical potential, with low toxicity and promising results. Despite these remarkable merits, further studies are needed to assess the safety and efficacy in humans. In addition, some in vivo experiments present inadequate methodologies, being carried out with low sample numbers and without details on randomization. Moreover, clinical studies should be encouraged to obtain more detailed results, including long-term toxicity, pharmacokinetic and pharmacodynamic parameters of these nanosystems.